Clinical Pharmacodynamic Assessments
tumor
PROLIFERATION, TUMOR
For pharmacodynamic analyses, tumor tissue was collected predose and at week 6 for evaluation of overall TIL, changes in activation, proliferation, and gene expression. MultiOmyx mIF, as described above, was used to characterize the immune phenotype of tumor-infiltrating immune populations using the following markers after custom validation of the antibody panel: ICOS, PD-1, PD-L1, OX40, Foxp3, CD4, CD8, granzyme B, Ki67, CD16, CD56, HLA-DR, S100, and PanCytokeratin.